Press Releases I-Mab

Equities

IMAB

US44975P1030

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-21 EDT			5-day change	1st Jan Change
1.68 ^USD	-0.59%		-8.70%	-11.58%

06-06	I-Mab Appoints Phillip Dennis as Chief Medical Officer	CI
06-05	I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	06-07	AQ
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	06-05	PR
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024	05-23	AQ
I-Mab to Participate at the Jefferies Global Healthcare Conference	05-22	PR
I-MAB Filed 2023 Annual Report on Form 20-F	04-30	PR
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	04-08	AQ
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	04-05	PR
I-Mab Announces Closing of the Divestiture of Business Operations in China	04-02	PR
I Mab : Resignations of Director and Senior Management - Form 6-K	04-01	PU
I-Mab Signs Agreement to Divest its Assets and Business Operations in China	02-08	AQ
I-Mab Announces Participation at Jefferies and Piper Conferences in November	11-06	PR
I-Mab - Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration for Primary Membranous Nephropathy	11-03	AQ
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023	11-01	PR
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023	23-10-16	PR
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503	23-10-11	AQ
I Mab : Regains Global Rights to Lemzoparlimab - Form 6-K	23-09-21	PU
I-Mab Announces Upcoming Participation at September Conferences	23-09-05	PR
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates	23-08-18	AQ
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023	23-08-08	PR
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma	23-07-11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases I-Mab

Equities

IMAB

US44975P1030

Press Releases

Filters